Tempest to Present at Two Upcoming Investor Conferences in November

Rhea-AI Summary

Tempest Therapeutics (Nasdaq: TPST) announced participation in two investor conferences this November. The company will present at the Jefferies London Healthcare Conference on November 18, 2021, with an on-demand presentation available at 8:00 a.m. GMT. Additionally, they will engage in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, available at 10:00 a.m. ET. Tempest is focused on developing innovative oncology therapeutics, including TPST-1495 and TPST-1120, which are currently in Phase 1 studies.

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the following investor conferences in November:

• Jefferies London Healthcare Conference – Company presentation available on-demand Thursday, November 18, 2021 at 8:00 a.m. GMT
• Piper Sandler 33rd Annual Virtual Healthcare Conference – Fireside chat available on-demand Monday, November 22, 2021 at 10:00 a.m. ET

To access the live or archived recording of the company presentaions, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. In collaboration with F. Hoffman La Roche, TPST-1120 is also advancing through a first line, global, randomized Phase 1b/2 clinical study evaluating TPST-1120 in combination with the standard-of-care regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contact:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media Contact:

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

What conferences will Tempest Therapeutics present at in November 2021?

Tempest Therapeutics will present at the Jefferies London Healthcare Conference on November 18, 2021, and at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021.

What are the dates and times of Tempest Therapeutics' presentations?

The Jefferies London Healthcare Conference presentation is available on-demand on November 18, 2021, at 8:00 a.m. GMT, and the Piper Sandler conference fireside chat is available on-demand on November 22, 2021, at 10:00 a.m. ET.

What is the focus of Tempest Therapeutics' clinical programs?

Tempest Therapeutics is focusing on developing small molecules that combine targeted and immune-mediated mechanisms, with clinical programs including TPST-1495 and TPST-1120.

What is the significance of TPST-1120 in clinical studies?

TPST-1120 is advancing through a global Phase 1b/2 clinical study in combination with atezolizumab and bevacizumab for the treatment of advanced or metastatic hepatocellular carcinoma.

Where can investors access Tempest Therapeutics' presentations?

Investors can access the live or archived recordings of the presentations on the investor section of Tempest Therapeutics' website.